Table 4.

ADP-induced platelet aggregation in platelet-rich plasma in the presence of the compounds 7, 8, 15–18, 23, 24, 35, 37, 39 and 40.

Compound	0	10 μM		50 μM
7	656.2 ± 55.8	686.5 ± 66.1	n.s.	642.8 ± 45.4	n.s.
8	654.9 ± 123.1	695.3 ± 133.4	n.s.	623.4 ± 165.6	n.s.
15	654.8 ± 57.5	698.7 ± 74.4	n.s.	657.1 ± 70.7	n.s.
16	648.5 ± 45.0	662.3 ± 67.0	n.s.	641.1 ± 35.1	n.s.
17	677.7 ± 65.5	646.2 ± 58.6	P < 0.001	639.5 ± 64.7	n.s.
18	708.9 ± 64.5	630.0 ± 80.3	P < 0.01	336.8 ± 108.5	P < 0.001
23	657.1 ± 57.8	715.3 ± 85.8	n.s.	657.0 ± 67.2	n.s.
24	678.9 ± 70.9	649.5 ± 70.2	P < 0.001	548.6 ± 72.2	P < 0.01
35	655.6 ± 38.8	665.7 ± 86.8	n.s.	682.3 ± 17.4	n.s.
37	651.4 ± 59.9	661.1 ± 61.3	n.s.	616.0 ± 24.7	P< 0.05
39	663.0 ± 54.6	678.4 ± 55.7	n.s.	658.0 ± 46.8	n.s.
40	641.1 ± 85.5	566.4 ± 112.9	P < 0.05	289.5 ± 158.9	P < 0.001

Data are presented as the means ± SD, n = 6–9 samples. The results are shown as the area under an aggregation curve measured in arbitrary units and was calculated as the extent of aggregation (a.u.) × time [min]. The significance of the inhibitory effect was tested in a pairwise manner (control vs. compound) using the bootstrap-boosted (10000 iterations) paired one-tailed Student’s t-test. Inhibitory effects greater than 50% are marked in bold. n.s. = nonsignificant.